25
May
This year is shaping up as the first we’ve seen in which biotech and healthcare startups receive a majority of U.S. Series A commitments. So far in 2024, biotech and health companies have pulled in around $5.6 billion across 110 Series A rounds, per Crunchbase data. That accounts for 53% of all funding at the Series A stage, which is a closely watched barometer for the startup ecosystem. The biotech sector’s comparatively strong showing comes as overall Series A dealmaking looks on track to come in a bit above last year’s totals. However, funding remains down from 2022 and much,…